Suppr超能文献

CD133在人胚肾293细胞中诱导肿瘤起始特性。

CD133 induces tumour-initiating properties in HEK293 cells.

作者信息

Canis Martin, Lechner Axel, Mack Brigitte, Zengel Pamela, Laubender Rüdiger Paul, Koehler Udo, Heissmeyer Vigo, Gires Olivier

机构信息

Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Centre, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.

出版信息

Tumour Biol. 2013 Feb;34(1):437-43. doi: 10.1007/s13277-012-0568-z. Epub 2012 Nov 13.

Abstract

The pentaspan protein CD133 (Prominin-1) is part of the signature of tumour-initiating cells for various cancer entities. The aim of the present study was to investigate the impact of ectopic CD133 expression on tumourigenic properties of otherwise CD133-negative, non-tumourigenic cells in vitro and in vivo. CD133 was stably transfected into human embryonic kidney 293 (HEK293) which was then sorted for the expression of CD133. The effects of CD133 on cell proliferation were assessed upon standard cell counting of sorted cells at various time points. Severe combined immunodeficient (SCID) mice (n = 30) were injected with HEK293 CD133(high) and CD133(low) transfectants (5 × 10(3), 1 × 10(5), or 5 × 10(6) cells per injection). The expression of CD133, Ki67, CD44s, CD44v6, and EpCAM was analysed upon immunohistochemical staining of cryosections with specific antibodies. In vitro, ectopic expression of CD133 did influence neither cell proliferation nor cell cycle distribution of otherwise CD133-negative HEK293 cells. However, CD133(high) cells generated tumours in vivo in SCID mice with at least 1,000-fold increased frequency compared to CD133(low) cells. Tumour load was also significantly increased in CD133(high) cells as compared to those tumours formed by high numbers of CD133(low) cells. Immunohistochemistry stainings disclosed no changes in Ki67, CD44s, CD44v6, or EpCAM once tumours were formed by either cell type. CD133 induces tumour-initiating properties in HEK293 cells in vivo and is potentially involved in the regulation of tumourigenicity. Future research will aim at the elucidation of molecular mechanisms of CD133-induced tumourigenicity.

摘要

五跨膜蛋白CD133(Prominin-1)是多种癌症实体中肿瘤起始细胞特征的一部分。本研究的目的是在体外和体内研究异位表达CD133对原本CD133阴性的非致瘤细胞致瘤特性的影响。将CD133稳定转染到人胚肾293(HEK293)细胞中,然后对其进行CD133表达分选。在不同时间点对分选后的细胞进行标准细胞计数,评估CD133对细胞增殖的影响。将严重联合免疫缺陷(SCID)小鼠(n = 30)注射HEK293 CD133(高表达)和CD133(低表达)转染细胞(每次注射5×10³、1×10⁵或5×10⁶个细胞)。用特异性抗体对冰冻切片进行免疫组织化学染色,分析CD133、Ki67、CD44s、CD44v6和EpCAM的表达。在体外,CD133的异位表达对原本CD133阴性的HEK293细胞的细胞增殖和细胞周期分布均无影响。然而,与CD133(低表达)细胞相比,CD133(高表达)细胞在SCID小鼠体内产生肿瘤的频率至少增加了1000倍。与大量CD133(低表达)细胞形成的肿瘤相比,CD133(高表达)细胞的肿瘤负荷也显著增加。免疫组织化学染色显示,无论哪种细胞类型形成肿瘤,Ki67、CD44s、CD44v6或EpCAM均无变化。CD133在体内诱导HEK293细胞的肿瘤起始特性,并可能参与致瘤性的调控。未来的研究将致力于阐明CD133诱导致瘤性的分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad87/3549409/6b9c193e4108/13277_2012_568_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验